
Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.
Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human microbiome-derived bacteria, today announced that Pfizer Inc. (NYSE: PFE) has made a $25 […]